0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ultrasound-guided noninvasive pancreas ablation using histotripsy: feasibility study in an in vivo porcine model

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pancreatic cancer is a malignant disease associated with poor survival and nearly 80% present with unresectable tumors. Treatments such as chemotherapy and radiation therapy have shown overall improved survival benefits, albeit limited. Histotripsy is a noninvasive, non-ionizing, and non-thermal focused ultrasound ablation modality that has shown efficacy in treating hepatic tumors and other malignancies. In this novel study, we investigate histotripsy for noninvasive pancreas ablation in a pig model. In two studies, histotripsy was applied to the healthy pancreas in 11 pigs using a custom 32-element, 500 kHz histotripsy transducer attached to a clinical histotripsy system, with treatments guided by real-time ultrasound imaging. A pilot study was conducted in 3 fasted pigs with histotripsy applied at a pulse repetition frequency (PRF) of 500 Hz. Results showed no pancreas visualization on coaxial ultrasound imaging due to overlying intestinal gas, resulting in off-target injury and no pancreas damage. To minimize gas, a second group of pigs ( n = 8) were fed a custard diet containing simethicone and bisacodyl. Pigs were euthanized immediately ( n = 4) or survived for 1 week ( n = 4) post-treatment. Damage to the pancreas and surrounding tissue was characterized using gross morphology, histological analysis, and CT imaging. Results showed histotripsy bubble clouds were generated inside pancreases that were visually maintained on coaxial ultrasound ( n = 4), with 2 pigs exhibiting off-target damage. For chronic animals, results showed the treatments were well-tolerated with no complication signs or changes in blood markers. This study provides initial evidence suggesting histotripsy’s potential for noninvasive pancreas ablation and warrants further evaluation in more comprehensive studies.

          Related collections

          Most cited references59

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer statistics, 2020

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pancreatic cancer

            Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use. Patients typically present with advanced disease due to lack of or vague symptoms when the cancer is still localised. High quality computed tomography with intravenous contrast using a dual phase pancreatic protocol is typically the best method to detect a pancreatic tumour and to determine surgical resectability. Endoscopic ultrasound is an increasingly used complementary staging modality which also allows for diagnostic confirmation when combined with fine needle aspiration. Patients with pancreatic cancer are often divided into one of four categories based on extent of disease: resectable, borderline resectable, locally advanced, and metastatic; patient condition is also an important consideration. Surgical resection represents the only chance for cure, and advancements in adjuvant chemotherapy have improved long-term outcomes in these patients. Systemic chemotherapy combinations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel remain the mainstay of treatment for patients with advanced disease. Data on the benefit of PARP inhibition as maintenance therapy in patients with germline BRCA1 or BRACA2 mutations might prove to be a harbinger of advancement in targeted therapy. Additional research efforts are focusing on modulating the pancreatic tumour microenvironment to enhance the efficacy of the immunotherapeutic strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After.

              In 2005, the International Study Group of Pancreatic Fistula developed a definition and grading of postoperative pancreatic fistula that has been accepted universally. Eleven years later, because postoperative pancreatic fistula remains one of the most relevant and harmful complications of pancreatic operation, the International Study Group of Pancreatic Fistula classification has become the gold standard in defining postoperative pancreatic fistula in clinical practice. The aim of the present report is to verify the value of the International Study Group of Pancreatic Fistula definition and grading of postoperative pancreatic fistula and to update the International Study Group of Pancreatic Fistula classification in light of recent evidence that has emerged, as well as to address the lingering controversies about the original definition and grading of postoperative pancreatic fistula.
                Bookmark

                Author and article information

                Journal
                8508395
                4857
                Int J Hyperthermia
                Int J Hyperthermia
                International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
                0265-6736
                1464-5157
                24 January 2024
                2023
                05 February 2024
                : 40
                : 1
                : 2247187
                Affiliations
                [a ]Department of Biomedical Engineering and Mechanics, VA Tech, Blacksburg, VA, USA
                [b ]Department of Biomedical Sciences and Pathobiology, Virginia-MD College of Veterinary Medicine, Blacksburg, VA, USA
                [c ]Graduate Program in Translational Biology, Medicine and Health, Virginia Tech, Roanoke, VA, USA
                [d ]DeBusk College of Osteopathic Medicine, Lincoln Memorial University, Knoxville, TN, USA
                [e ]Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, US
                [f ]Department of Basic Science Education, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA
                [g ]Department of Radiology, MI Medicine, Ann Arbor, MI
                [h ]Interventional Oncology Institute Khuab, Comprehensive Tumor Center, Barcelona, Spain
                [i ]Department of Surgery, Carilion Clinic, Roanoke, VA, USA
                [j ]Department of Large Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, USA
                [k ]ICTAS Center for Engineering Health, Virginia Tech, Blacksburg, VA
                Author notes
                CONTACT Eli Vlaisavljevich eliv@ 123456vt.edu Department of Biomedical Engineering and Mechanics, VA Tech, Blacksburg, VA, USA; Irving Coy Allen icallen@ 123456vt.edu Department of Biomedical Sciences and Pathobiology, Virginia-MD College of Veterinary Medicine, Blacksburg, VA, USA
                Author information
                http://orcid.org/0000-0002-0466-2613
                http://orcid.org/0000-0003-0755-8499
                http://orcid.org/0000-0001-8561-8288
                http://orcid.org/0000-0002-7291-4907
                http://orcid.org/0000-0001-6687-6476
                http://orcid.org/0000-0001-5309-5830
                http://orcid.org/0000-0003-4055-916X
                http://orcid.org/0000-0001-7199-7272
                http://orcid.org/0000-0001-7385-3969
                http://orcid.org/0000-0001-9573-5250
                http://orcid.org/0000-0002-4097-6257
                Article
                NIHMS1961818
                10.1080/02656736.2023.2247187
                10839746
                37643768
                c4368a32-71d7-47aa-8425-dad32494e7c9

                This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ( http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

                History
                Categories
                Article

                Medicine
                pancreas,pancreatic cancer,histotripsy,large animal model,focused ultrasound
                Medicine
                pancreas, pancreatic cancer, histotripsy, large animal model, focused ultrasound

                Comments

                Comment on this article